Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did. Read how
Close

Agennix AG (AGXG)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Agennix AG historical data, for real-time data please try another search
0.003 0.000    0.00%
04/02 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.003 - 0.003
Type:  Equity
Market:  Germany
ISIN:  DE000A1A6XX4 
S/N:  A1A6XX
Agennix AG 0.003 0.000 0.00%

Agennix AG Company Profile

 
Get an in-depth profile of Agennix AG, including a general overview of the company's business and key management, as well as employee data and location and contact information.
Industry
Sector
Employees

52

Equity Type

ORD

Agennix AG operates as a biopharmaceutical company in Princeton, New Jersey. It focuses on developing novel therapies that have the potential to lengthen and enhance the lives of critically ill patients in the areas of unmet medical need. The company’s lead product candidate under development is Talactoferrin, an oral dendritic cell that establishes and functions body’s immune system, which has completed Phase III trial enrollment for the treatment of non-small cell lung cancer; and Phase II clinical trial for the treatment of severe sepsis. Its developmental stage products include topical talactoferrin, which has completed Phase IIa clinical trial for the treatment of diabetic foot ulcers; satraplatin, an oral platinum gel that has completed Phase I trial for oncology; and RGB-286638, a multi-targeted kinase inhibitor that has completed Phase I trial for the treatment of solid tumors. The company was founded in 1993 and is based in Heidelberg, Germany.

Contact Information

Address Im Neuenheimer Feld 515
Heidelberg, 69120
Germany
Phone -
Fax -
Web www.agennix.com
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

AGXG Comments

Write your thoughts about Agennix AG
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email